Incannex Healthcare (IXHL) Stock News

Incannex Healthcare (NASDAQ: IXHL) has formed a 50:50 joint venture with Mind Medicine Australia (MMA) to operate a psychedelic-assisted therapies clinic in Melbourne. The new entity, Mind Medicine Australia Clinics, will provide integrated services including clinical operations, governance, medicine supply, medical oversight, and marketing support to Authorised Prescribers across Australia. The venture aims to expand treatment access by reducing costs and tripling capacity for patients with PTSD, treatment-resistant depression, and other mental health conditions. MMA, Australia's leading non-profit in psychedelic-assisted therapies, previously achieved the world's first regulatory rescheduling of psilocybin and MDMA for clinical use in 2023. The partnership leverages MMA's expertise, including their Certificate in Psychedelic-Assisted Therapies (CPAT) program, to establish a Centre of Excellence for delivering and advancing psychedelic-assisted treatments.

Incannex Healthcare (IXHL) has successfully canceled all remaining Series A Warrants through its ATM facility, eliminating 347.2 million shares from potential future dilution. The company executed binding agreements to cancel the final 172 million Series A Warrants for $12.2 million, following an earlier cancellation in May 2025. This strategic move streamlines Incannex's capital structure ahead of crucial Phase 2 clinical milestones, particularly the upcoming topline data readout from the RePOSA trial of IHL-42X for obstructive sleep apnea expected in July 2025. IHL-42X is being developed as a potential first-in-class oral therapy for sleep apnea, addressing a significant market gap as there are currently no FDA-approved drug treatments for this condition that affects millions globally.

Incannex Healthcare (NASDAQ: IXHL) has expanded its IHL-42X Clinical Advisory Board with four distinguished experts to advance its Obstructive Sleep Apnea (OSA) program. The new appointments include Harvard Medical School professors Scott A. Sands and Ali Azarbarzin, neurologist Lora J. McGill, and Emory Sleep Center Director Nancy Collop. This strategic expansion comes at a crucial time as Incannex prepares to announce IHL-42X Phase 2 topline data in July 2025 and initiate its Phase 3 U.S. study later in the year. The advisory board will provide expertise for IHL-42X, an oral once-daily treatment for OSA, through its late-stage development. The appointed experts bring extensive experience in sleep medicine, clinical research, and OSA pathophysiology.

Incannex Healthcare (NASDAQ: IXHL) has received FDA clearance to advance its IHL-42X RePOSA clinical trial to Phase 3 for treating obstructive sleep apnea (OSA). The trial will evaluate IHL-42X, which aims to become the first FDA-approved oral therapy for OSA, a condition affecting approximately one billion people globally.

The Phase 3 study will be conducted exclusively in the U.S., building on the Phase 2 infrastructure. The trial will involve approximately 30 sites (20 existing and 10 new) and will evaluate the drug's safety and efficacy over 12 months. The study includes a 3-month head-to-head comparison against dronabinol and acetazolamide to demonstrate the combination therapy's synergistic effect. The primary endpoint will measure changes in the Apnea-Hypopnea Index (AHI).

Incannex Healthcare (NASDAQ: IXHL) has entered a binding agreement to cancel 172 million Series A Warrants for a payment of up to $12.2 million. This follows a previous cancellation of 175.2 million warrants announced on May 20, 2025, bringing the total elimination to 347.2 million potential dilutive shares. The strategic move comes ahead of the company's anticipated Phase 2 RePOSA trial topline results for IHL-42X, their oral treatment for obstructive sleep apnea, expected in July 2025. IHL-42X is being developed as a potential first-in-class treatment for sleep apnea, a condition currently lacking FDA-approved drug therapies.

Incannex Healthcare (Nasdaq: IXHL) has successfully raised $16.7 million through an at-the-market (ATM) facility, with $12.5 million allocated to cancel up to 50.4% of its Series A Warrants. This strategic move will eliminate the potential issuance of up to 175.2 million additional shares that could have resulted from warrant adjustment features. The cancellation affects up to 5,841,038 warrants from a previous financing agreement.

CEO Joel Latham emphasized that this initiative reduces significant stock overhang and demonstrates the company's commitment to responsible capital management. The timing is particularly strategic as it precedes the upcoming Phase 2 IHL-42X results. The company plans to continue evaluating additional strategic initiatives to improve its capital structure.

Incannex Healthcare (NASDAQ: IXHL) has entered into agreements with Series A Warrant holders that could potentially reduce up to 50.4% of the shares underlying these warrants. The company plans to use approximately $12.5 million from its ATM sales agreement with A.G.P/Alliance Global Partners to pay warrant holders for canceling up to 5,833,333 shares of common stock (adjustable to 175,000,000 shares at a floor price of $0.216 per share).

The Series A Warrants remain unexercisable pending stockholder approval, which will be sought at a special meeting scheduled for May 27, 2025. This move aims to reduce potential dilution for existing stockholders while the company continues to advance its IHL-42X treatment for obstructive sleep apnea.

Incannex Healthcare (Nasdaq: IXHL) reported its Q3 FY2025 financial results and business updates. The company secured $12.5 million in private placement funding to support its IHL-42X Phase 2/3 OSA clinical program. The company completed dosing of over 120 patients across 11 clinical sites in the Phase 2 portion of the RePOSA study, evaluating two doses of IHL-42X for obstructive sleep apnea treatment.

Financial highlights include reduced losses with net loss of $3.97 million (vs $6.03 million in Q3 2024), G&A expenses of $2.27 million (vs $4.14 million), and R&D expenses of $2.74 million (vs $3.28 million). Cash position improved to $6.71 million as of March 31, 2025. Topline data from the Phase 2 study is expected in July 2025, with Phase 3 planning underway exclusively at U.S. sites.

Incannex Healthcare (NASDAQ: IXHL) has completed patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study for IHL-42X, a potential first-in-class oral treatment for Obstructive Sleep Apnea (OSA). End-of-study follow-up assessments will conclude by May 17, 2025, with topline results expected in July 2025. The company plans to conduct Phase 3 trials exclusively in the U.S., recruiting 440 patients. In previous Phase 2 trials, IHL-42X showed promising results with a 51% average reduction in Apnea-Hypopnea Index (AHI) at the lowest dose. The drug targets two key physiological pathways: intermittent hypoxia and hypercapnia. Unlike weight loss therapies, IHL-42X could potentially treat a broader OSA population, including the 67% of patients who are not obese. The company is preparing for an end-of-Phase 2 FDA meeting and has begun preliminary commercial discussions.